Translational Sciences

UPMC Enterprises is proud to officially announce that a new portfolio company, Novasenta, has opened its doors to a new laboratory space on Technology drive in Pittsburgh. Novasenta discovers novel therapeutic targets to transform medicine in cancer and other debilitating diseases by using a proprietary, comprehensive screening platform.  

Werewolf Therapeutics, a biopharmaceutical company pioneering the development of therapeutics to stimulate the body’s immune …

Developing targeted non-viral vector gene therapies for rare and prevalent diseases

Over the last year, UPMC Enterprises, our portfolio companies, and select partners have all supported UPMC’s mission of Life Changing Medicine. In the booklet below, we have compiled highlights from a truly unique year and recognize the team members and projects that have enabled our success.

Jeanne Cunicelli has been named president of UPMC Enterprises succeeding Tal Heppenstall, who is retiring from UPMC after 17 years.

As the complexity of science and subsequent treatments increase, the way in which we foster …

With $1 billion to invest in life sciences startups, UPMC Enterprises will create a significant impact on patient care at UPMC while generating major financial returns that will fuel more scientific discoveries.

At UPMC, we are committed to building a health system where the right patient gets the right care, in the right way, at the right time, every time. The “Rights” of clinical management…

As 2019 comes to a close, we have seen many different trends and topics discussed on our blog. From new technologies and investments to breakthroughs in the digital health industry, we wanted to know what our team was most excited to see in 2020.

It has been a busy year at UPMC Enterprises. Here at the innovation and commercialization …